N4 Pharma (GB:N4P) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
N4 Pharma PLC has announced promising results from its latest oral delivery research for Nuvec®, a cutting-edge system designed for cancer treatments and vaccines. The study, in collaboration with the University of Queensland, showed that Nuvec® successfully delivered a plasmid DNA payload in the intestine, which led to significant protein expression and a strong antibody response. CEO Nigel Theobald expressed confidence in Nuvec®’s potential for various medical applications and outlined plans for continued research and development.
For further insights into GB:N4P stock, check out TipRanks’ Stock Analysis page.
